InvestorWire NewsRoom


Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) Leverages Genetics to Produce Potent CBD Strains Amid New Research Suggesting CBD Aids COVID-19 Patients
February 17, 2021

Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) Leverages Genetics to Produce Potent CBD Strains Amid New Research Suggesting CBD Aids COVID-19 Patients

  • Austrian researchers report CBD reduces inflammation and speeds recovery in ICU COVID-19 patients
  • Research suggests CBD’s anti-inflammatory properties stave off long-term neurological damage associated with COVID-19
  • PACR leverages genetic technology to produce potent CBD strains with higher yields per growing season
  • Company catalog includes 350 cultivars and 50 super-elite strains prized in industry

CBD may soon become the newest support in the world’s fight against COVID-19: Researchers at the Klagenfurt Clinic in Austria recently reported positive results from cannabidiol (“CBD”) trials on COVID-19 patients that demonstrated reduced inflammation and quicker recovery times ( Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated to producing premium-quality strains and products through a genetics-focused approach, leverages genetic technology to cultivate unique strains prized in the industry for their potency and overall effectiveness.

CBD continues to gain mainstream attention among healthcare professionals and the general public as a way to address symptoms of chronic diseases – particularly those associated with inflammation ( Accordingly, researchers at the Klagenfurt Clinic in Austria used CBD oil to treat COVID-19 ICU patients for three weeks and observed positive changes in inflammation markers throughout the treatment.

“We have seen that the inflammation parameters in the blood go down, and people leave the hospital faster than the comparison group,” said Rudolf Likar, head of intensive care medicine at the clinic. “CBD supports the immune system. We’ll probably use this routinely now because it doesn’t have any side effects.”

According to the researchers, CBD’s anti-inflammatory effects surpassed those of other commonly used drugs because of its ability to easily cross the blood-brain barrier and stave off some of the long-term neurological damage associated with the disease.

PACR’s genetics-based approach to cannabis cultivation has produced roughly 350 tested cultivars, including 50 super-elite strains with varying amounts of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) – two of over 140 known cannabinoids in the cannabis plant that can produce different effects on the body. The Company also uses genetic technology to optimize its cultivars to produce maximum yields according to varying climatic conditions and growing seasons with the potential to boost profit margins through reduced labor costs and increased output.

A critical competitive advantage that sets PACR apart is its strategic licensing agreement with Phenome One Corp – a privately-held full-service genetics cannabis company that gives PACR access to one of Canada’s largest living genetic cannabis libraries. Along with giving its partners access to a massive database of detailed information, Phenome One also subjects each cultivar to rigorous analysis and testing—a process that goes back more than 30 years.

The growing body of scientific evidence supporting the use of CBD along with increasingly relaxed laws around the use of cannabis is contributing to the ever-increasing market opportunity for cannabis cultivators. PacRoots Cannabis Corp. appears to be favorably positioned to benefit from the explosive growth in demand for their first-in-class high-yield strains that appeal to a wide variety of consumers across the rapidly growing legal cannabis market.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).